A5022267430- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Blood transfusion and management
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Immunotherapy and Immune Responses
- Hemostasis and retained surgical items
- Virus-based gene therapy research
- Platelet Disorders and Treatments
- CRISPR and Genetic Engineering
- Heparin-Induced Thrombocytopenia and Thrombosis
- PARP inhibition in cancer therapy
- Venous Thromboembolism Diagnosis and Management
- Blood donation and transfusion practices
- Endometriosis Research and Treatment
- Gastric Cancer Management and Outcomes
- Antiplatelet Therapy and Cardiovascular Diseases
- Blood groups and transfusion
- Cancer Genomics and Diagnostics
- Abdominal Trauma and Injuries
- Blood Coagulation and Thrombosis Mechanisms
- Hemoglobin structure and function
- Spectroscopy and Quantum Chemical Studies
- Protein Interaction Studies and Fluorescence Analysis
- Animal Virus Infections Studies
Big Horn Basin Regional Cancer Center
2024
University of Cincinnati Medical Center
2013-2023
Kettering University
2014-2023
University of Cincinnati
2013-2023
Kettering Medical Center
2021-2023
Memorial Sloan Kettering Cancer Center
2002-2022
University of Washington
2022
The Ohio State University
2022
University of Chicago
2022
Mayo Clinic in Florida
2022
Vascular endothelial growth factor (VEGF) promotes angiogenesis, a mediator of disease progression in cervical cancer. Bevacizumab, humanized anti-VEGF monoclonal antibody, has single-agent activity previously treated, recurrent disease. Most patients whom cancer develops have received cisplatin with radiation therapy, which reduces the effectiveness at time recurrence. We evaluated bevacizumab and nonplatinum combination chemotherapy recurrent, persistent, or metastatic cancer.Using 2-by-2...
Most of the amino acid side chains beef liver catalase were clearly identifiable in 2.5 A resolution electron-density map, and results are good agreement with sequence [Schroeder, W. A., Shelton, J. R., B., Roberson, B. & Apell, G. (1969) Arch. Biochem. Biophys. 131, 653-655]. The tertiary structure one subunit consists a large antiparallel beta-pleated sheet domain helical insertions, followed by smaller containing four alpha-helices. heme group is buried at least 20 below molecular...
To apply the International Ovarian Tumor Analysis (IOTA) Simple Rules (SR), IOTA risk assessment (SRR), Assessment of Different NEoplasias in adneXa (ADNEX) model and Ovarian-Adnexal Reporting Data System (O-RADS) same cohort North American patients to compare their performance preoperative discrimination between benign malignant adnexal lesions.
Background An advanced hemostatic dressing is needed to augment current methods for the control of life-threatening hemorrhage. A systematic approach study dressings described. We studied effects nine on blood loss using a model severe venous hemorrhage and hepatic injury in swine. Methods Swine were treated one dressings. Dressings used following primary active ingredients: microfibrillar collagen, oxidized cellulose, thrombin, fibrinogen, propyl gallate, aluminum sulfate, fully acetylated...
To characterize the molecular basis for hemostatic defects of dengue infections, a study was conducted in Bangkok, Thailand. Febrile children (n = 68) hospitalized with suspected were enrolled before their clinical syndromes classified as either fever (DF) or hemorrhagic (DHF). Hospital course and outcome recorded; blood obtained during febrile illness (S1), after defervescence (S2), 1 month onset disease (S4). Patients DF 21) DHF grades 1, 2, 3; (DHF1, n 8; DHF2, 30; DHF3, 9). All had...
In the randomized phase III trial, Gynecologic Oncology Group (GOG) protocol 240, incorporation of bevacizumab with chemotherapy significantly increased overall survival (OS) in women advanced cervical cancer. A major objective GOG-240 was to prospectively analyze previously identified pooled clinical prognostic factors known as Moore criteria.Potential negative included black race, performance status 1, pelvic disease, prior cisplatin, and progression-free interval <365 days. Risk...
The first page of this article is displayed as the abstract.
The majority of early trauma deaths are caused by uncontrolled hemorrhage, and frequently complicated hypothermic dilutional coagulopathies. Any hemorrhage-control technique that achieves rapid hemostasis despite a coagulopathy should improve the outcome these patients. We conducted this study to determine whether dry fibrin sealant dressings (DFSD) would stop bleeding from grade V liver injuries in swine were coagulopathic.Nineteen weighing 39.7 kg (mean 95% confidence interval, 36.3-43.1),...
To determine whether a non‑platinum chemotherapy doublet improves overall survival (OS) among patients with recurrent/metastatic cervical carcinoma.Gynecologic Oncology Group protocol 240 is phase 3, randomized, open-label, clinical trial that studied the efficacy of paclitaxel 175 mg/m2 plus topotecan 0.75 days 1-3 (n = 223) vs cisplatin 50 135 or 229), in 452 cancer. Each was also and without bevacizumab (15 mg/kg). Cycles were repeated every 21 until progression, unacceptable toxicity,...
3 The full, final text of this abstract will be available at abstract.asco.org 7:30 AM (EDT) on Sunday, June, 2, 2013, and in the Annual Meeting Proceedings online supplement to June 20, issue Journal Clinical Oncology. Onsite Meeting, printed Sunday edition ASCO Daily News.
This exploratory single-arm phase II study evaluated the efficacy and safety of RRx-001 followed by reintroduction platinum plus etoposide in patients with previously treated small-cell lung cancer (SCLC). Patients were 4 mg IV on day 1 each week a 21-day cycle at progression re-challenge 80–100 mg/m2 days 1, 2 3 cisplatin 60–80 or carboplatin AUC 5–6 every 21 days. The primary end points overall survival (OS) response rate to regimen. Twenty-six enroled received least one dose RRx-001....
The first page of this article is displayed as the abstract.
3 Background: Vascular endothelial growth factor (VEGF) promotes angiogenesis, a mediator of disease progression in cervical cancer. Bevacizumab (B), humanized anti-VEGF monoclonal antibody, has shown single-agent activity pretreated recurrent disease. We aimed to evaluate B chemotherapy (CTX)-naive recurrent/persistent/metastatic Methods: Using 2x2 factorial design, patients were randomly assigned CTX with or without 15 mg/kg. The regimens included cisplatin 50 mg/m 2 plus paclitaxel...
In the Phase 3 VELIA trial (NCT02470585), PARP inhibitor (PARPi) veliparib was combined with first-line chemotherapy and continued as maintenance for patients ovarian carcinoma enrolled regardless of response or biomarker status. Here, we report exploratory analyses impact homologous recombination deficient (HRD) proficient (HRP) status on progression-free survival (PFS) objective rates during chemotherapy.Women Stage III-IV were randomized to veliparib-throughout,...
LBA5515 Background: Batiraxcept is an Fc-fusion protein engineered to have a 200-fold higher affinity than wild-type AXL for its activating ligand GAS6. sequesters GAS6 and inhibits interaction with AXL. The Phase 1b study demonstrated safety batiraxcept in combination paclitaxel. Methods: This was global, placebo-controlled, double-blind, phase III trial (ClinicalTrials.gov identifier: NCT04729608). Patients PROC were randomly assigned 1:1 receive intravenous every 2 weeks (D1, 15 28 days)...
Views Icon Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Twitter Facebook Reddit LinkedIn Tools Reprints and Permissions Cite Search Site Citation T. L. Cottrell, J. Reid; The Thermal Decomposition of Nitromethane. Chem. Phys. 1 September 1950; 18 (9): 1306. https://doi.org/10.1063/1.1747945 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Dropdown Menu input auto suggest filter...